Explaining the Prescription Drug Provisions in the Build Back Better Act
By Juliette Cubanski, Tricia Neuman, and Meredith Freed
Kaiser Family Foundation
On November 19, 2021, the House of Representatives passed H.R. 5376, the Build Back Better Act (BBBA), which includes a broad package of health, social, and environmental proposals supported by President Biden. The BBBA includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. These proposals have taken shape amidst strong bipartisan, public support for the government to address high and rising drug prices. CBO estimates that the drug pricing provisions in the BBBA would reduce the federal deficit by $297 billion over 10 years (2022-2031).
The key prescription drug proposals included in the BBBA would:
– Allow the federal government to negotiate prices for some high-cost drugs covered under Medicare Part B and Part D
– Require inflation rebates to limit annual increases in drug prices in Medicare and private insurance
– Cap out-of-pocket spending for Medicare Part D enrollees and other Part D benefit design changes
– Limit cost sharing for insulin for people with Medicare and private insurance
– Eliminate cost sharing for adult vaccines covered under Part D
– Repeal the Trump Administration’s drug rebate rule
This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation. We incorporate the estimated budgetary effects released by CBO on November 18, 2021, and to provide additional context for understanding the expected budgetary effects, we point to past projections of similar legislative proposals from CBO and others. This summary is based on the legislative language included in the House-passed bill that may be modified as it moves through the Senate.
This article originally appeared on KFF.org. Click here to read the full brief.
Recent Posts
-
Experts fear damage to long-term care pharmacies as CMS touts newly negotiated drug prices
Even as the federal government on Thursday touted the billions of dollars in savings seniors can expect to see from newly negotiated, lower drug costs, pharmacies that supply long-term care facilities are warning of dire consequences.
-
Senior Care Pharmacy Coalition & “Save Senior Rx Care” Release Statement on Biden Administration’s Medicare Drug Pricing Announcement
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, and the new Save Senior Rx Care campaign released a statement today in response to the new drug pricing announcement: “Today, the Biden Administration released the negotiated 2026 prices for the ten most expensive Medicare Part D drugs, as […]
-
LTC pharmacies demand ‘sustainable’ payment model ahead of 2026 drug-pricing changes
Many of the nation’s long-term care pharmacies are going to fall below “break-even” and may be forced out of business without additional support when drug-pricing policy changes kick in, sector advocates warned Wednesday.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.